These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26784539)

  • 41. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
    Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
    Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.
    Shetty V; Sinnathamby G; Nickens Z; Shah P; Hafner J; Mariello L; Kamal S; Vlahović G; Lyerly HK; Morse MA; Philip R
    J Proteomics; 2011 May; 74(5):728-43. PubMed ID: 21362506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
    Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
    Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo.
    Medina F; Ramos M; Iborra S; de León P; Rodríguez-Castro M; Del Val M
    J Immunol; 2009 Oct; 183(7):4639-47. PubMed ID: 19752221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
    Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
    Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules.
    Daniel S; Brusic V; Caillat-Zucman S; Petrovsky N; Harrison L; Riganelli D; Sinigaglia F; Gallazzi F; Hammer J; van Endert PM
    J Immunol; 1998 Jul; 161(2):617-24. PubMed ID: 9670935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.
    Ashi MO; Mami-Chouaib F; Corgnac S
    Explor Target Antitumor Ther; 2022; 3(6):746-762. PubMed ID: 36654823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
    Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
    J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trick to treat: tricking the thymus to treat cancer.
    Bonini C; Mondino A
    Blood; 2013 Jul; 122(3):304-6. PubMed ID: 23869073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TEIPP peptides: exploration of unTAPped cancer antigens.
    Marijt KA; Van Der Burg SH; van Hall T
    Oncoimmunology; 2019; 8(8):1599639. PubMed ID: 31413908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refusing to TAP out: 16 new human TEIPPs identified.
    Gigoux M; Wolchok J
    J Exp Med; 2018 Sep; 215(9):2233-2234. PubMed ID: 30131364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
    Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
    J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.